Brook StarRay Wireless Controller Now Available — Native PS5 Support Meets Xbox-Style Control
OpenWorld (NASDAQ: OPNW) Signs Definitive Merger Agreement to Acquire Blocksight
Scalare Launches EquityRoom, Adding a Subscription Revenue Stream to Its Founder Ecosystem
Megaannum Capital and Zhongke Xianxing Venture Capital Enter into Strategic Partnership
Airtripmaker Expands Business and First-class Flights Network to London, Amsterdam, Frankfurt, Tokyo, Sydney by Introducing Enhanced Coverage for Global Destinations as Part of Its Ongoing Growth Strategy
New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to…
New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to…
CHASKA, Minn., May 22, 2023 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (“Lifecore” or the “Company”),…
CHASKA, Minn., May 22, 2023 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (“Lifecore” or the “Company”),…
The Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) in Conjunction with the…
The Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) in Conjunction with the…
PHILADELPHIA, May 22, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq:…
PHILADELPHIA, May 22, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq:…
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM…
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM…
IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended…
IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended…
TERN-601 (oral GLP-1) program in obesity on track to initiate Phase 1 clinical trial in…
TERN-601 (oral GLP-1) program in obesity on track to initiate Phase 1 clinical trial in…
Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023…
Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023…
9 poster presentations and 3 abstracts publications reinforce Galapagos’ commitment to immunology and the rheumatoid…
AIM nanoparticle approach can identify select EBV-specific T cell defects in patients with multiple sclerosis…
OLD GREENWICH, Conn.–(BUSINESS WIRE)–Ellington Financial Inc. (NYSE: EFC) (the “Company”) today announced that at its…
Divests Non-Core Businesses in a Company Reset to Maximize Opportunities in the Esports and E-simulator…